ABEO
USDAbeona Therapeutics Inc. Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$6.200
最高
$6.310
最低
$6.100
交易量
0.72M
公司基本面
市值
319.5M
行業
生物科技
國家
United States
交易統計
平均交易量
1.67M
交易所
NCM
貨幣
USD
52週範圍
相關新聞
Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19
Oppenheimer analyst Andreas Argyrides assumes Abeona Therapeutics with a Outperform rating and announces Price Target of $19.
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in
Stifel Maintains Buy on Abeona Therapeutics, Lowers Price Target to $20
Stifel analyst Dae Gon Ha maintains Abeona Therapeutics with a Buy and lowers the price target from $21 to $20.
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital
